{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=29", "query": { "intervention": "High Dose Drug A", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 1666, "total_pages": 167, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T15:02:09.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07115368", "title": "Study of GS-1219 in Participants With HIV-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-1219", "type": "DRUG" }, { "name": "BVY", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2025-08-11", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115368" }, { "nct_id": "NCT01802723", "title": "Dose Ranging Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Periumbilical Subcutaneous Adipose Tissue Reduction" ], "interventions": [ { "name": "Drug: salmeterol xinafoate", "type": "DRUG" }, { "name": "Drug: Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neothetics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 472, "start_date": "2013-02", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2015-03-26", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 22, "location_summary": "Beverly Hills, California • Encinitas, California • Los Angeles, California + 19 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802723" }, { "nct_id": "NCT01211483", "title": "Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC (Advanced Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "U3-1287", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2010-09", "completion_date": "2013-11-23", "has_results": true, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 14, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01211483" }, { "nct_id": "NCT07226362", "title": "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety, and Tolerability" ], "interventions": [ { "name": "DHE inhalation powder low dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE inhalation powder high dose administered via dry powder inhaler (DPI) device", "type": "COMBINATION_PRODUCT" }, { "name": "DHE injected intravenously (1 mg)", "type": "DRUG" }, { "name": "DHE 2 mg administered by nasal spray (Migranal®)", "type": "DRUG" }, { "name": "Metoclopramide 10mg", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Aspeya Switzerland SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2025-06-09", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226362" }, { "nct_id": "NCT04794205", "title": "Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Beta-Caryophyllene" ], "interventions": [ { "name": "Low Dose Beta-Caryophyllene", "type": "DRUG" }, { "name": "Medium Dose Beta-Caryophyllene", "type": "DRUG" }, { "name": "High Dose Beta-Caryophyllene", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hartford Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": "2021-09", "completion_date": "2022-04", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 1, "location_summary": "Hartford, Connecticut", "locations": [ { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04794205" }, { "nct_id": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2019-11-11", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143711" }, { "nct_id": "NCT00353652", "title": "Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Study#1: chlorthalidone (CTD), titrated dose", "type": "DRUG" }, { "name": "Study #1: spironolactone (SP), titrated dose", "type": "DRUG" }, { "name": "Study# 2 chlorthalidone (CTD), fixed dose", "type": "DRUG" }, { "name": "Study# 2 spironolactone (SP), fixed dose", "type": "DRUG" }, { "name": "Study# 2 irbsesartan (IR), fixed dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 166, "start_date": "2005-01", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2019-02-06", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00353652" }, { "nct_id": "NCT05846230", "title": "Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchiectasis" ], "interventions": [ { "name": "BI 1291583", "type": "DRUG" }, { "name": "Placebo matching BI 1291583", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 268, "start_date": "2023-09-08", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 11, "location_summary": "Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05846230" }, { "nct_id": "NCT01187511", "title": "CRF1 Antagonist GSK561679 in Alcoholism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Dependence" ], "interventions": [ { "name": "GSK561679", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 44, "start_date": "2010-01", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01187511" }, { "nct_id": "NCT05551936", "title": "A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vaishalee Kenkre", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2023-01-26", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-11-15T15:02:09.891Z", "location_count": 5, "location_summary": "Chicago, Illinois • New Brunswick, New Jersey • Columbus, Ohio + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551936" } ] }